College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, MB, Canada; Vaccine and Drug Evaluation Centre, University of Manitoba, MB, Canada; George & Fay Yee Centre for Healthcare Innovation, University of Manitoba, MB, Canada.
George & Fay Yee Centre for Healthcare Innovation, University of Manitoba, MB, Canada.
Curr Probl Cancer. 2021 Apr;45(2):100646. doi: 10.1016/j.currproblcancer.2020.100646. Epub 2020 Sep 4.
Cancer patients are among high-risk individuals for whom seasonal influenza vaccine (SIV) is recommended, but rates of vaccination in this subpopulation remain suboptimal; even in jurisdictions with universal influenza vaccination programs. We sought to summarize the evidence to better understand the determinants of SIV uptake (vaccine receipt) among cancer patients. We searched MEDLINE, Embase, and CINAHL from 2000 to February 12, 2020, focusing on articles on the determinants of seasonal influenza vaccination among cancer patients, published in English. Study selection was conducted independently by 2 reviewers. One reviewer extracted data from the included studies and another reviewer checked the extracted data for errors. Outcomes were sociodemographic and health-related factors. We pooled adjusted results from studies using the inverse variance, random-effects method, and reported the odds ratios (OR) and their 95% confidence intervals (CI). Out of 2664 citations, 10 studies (mostly from USA and South Korea) met our eligibility criteria. Overall, being older (OR 2.23, 95% CI 1.46-3.38; I 92.3%, [6 studies]), a nonsmoker (1.43, 1.32-1.51; I 0%, [4 studies]), having a chronic illness (1.18, 1.07-1.29; I 15.7%, [5 studies]), having had a medical check-up in the past year (1.75, 1.65-1.86; I 0%, [2 studies]), and having health insurance (1.39, 1.13-1.72; I 21.8%, [3 studies]) were associated with increased SIV uptake. Compared with being African-American, being Caucasian was also associated with increased SIV uptake (1.79, 1.47-2.13; I 10.7%, [3 studies]). Limited evidence suggests seasonal influenza vaccination among cancer patients may be determined by some sociodemographic and health-related factors.
癌症患者属于建议接种季节性流感疫苗（SIV）的高危人群，但该人群的疫苗接种率仍然不理想；即使在有普及流感疫苗接种计划的司法管辖区也是如此。我们试图总结证据，以更好地了解癌症患者 SIV 接种（疫苗接种）的决定因素。我们检索了 2000 年至 2020 年 2 月 12 日的 MEDLINE、Embase 和 CINAHL，重点关注发表在英语期刊上的有关癌症患者季节性流感疫苗接种决定因素的文章。两位审稿人独立进行了研究选择。一位审稿人从纳入的研究中提取数据，另一位审稿人检查提取数据是否存在错误。结果是社会人口统计学和与健康相关的因素。我们使用逆方差、随机效应方法汇总了使用 SIV 的研究结果，并报告了优势比（OR）及其 95%置信区间（CI）。在 2664 条引用文献中，有 10 项研究（主要来自美国和韩国）符合我们的纳入标准。总体而言，年龄较大（OR 2.23，95%CI 1.46-3.38；I 92.3%，[6 项研究]）、不吸烟（1.43，1.32-1.51；I 0%，[4 项研究]）、患有慢性病（1.18，1.07-1.29；I 15.7%，[5 项研究]）、过去一年接受过体检（1.75，1.65-1.86；I 0%，[2 项研究]）和有医疗保险（1.39，1.13-1.72；I 21.8%，[3 项研究]）与增加 SIV 接种率有关。与非裔美国人相比，白种人也与增加 SIV 接种率有关（1.79，1.47-2.13；I 10.7%，[3 项研究]）。有限的证据表明，癌症患者的季节性流感疫苗接种可能取决于一些社会人口统计学和与健康相关的因素。
